中文
English
한국어
日本語
Español
Français
Русский
| 카탈로그 번호 | CY257020 |
|---|---|
| 설명 |
InVivoMAb Anti-Dog CD20/MS4A1 Antibody (Iv0177) [Iv0177] (CY257020) is a dog monoclonal antibody detecting B-lymphocyte surface antigen B1 in ELISA, Neutralization. Suitable for Dog.
|
| 종 반응성 | Canine |
| 응용 분야 | ELISA, Neutralization |
| 숙주 종 | Canine |
| 클론성 | Monoclonal |
| 이소타입 | IgG2, kappa |
| 클론 ID | Iv0177 |
| 타겟 | B-lymphocyte antigen CD20, B-lymphocyte surface antigen B1, Bp35, CD20, Leukocyte surface antigen Leu-16, MS4A1, Membrane-spanning 4-domains subfamily A member 1 |
| 내독소 수준 | < 1 EU/mg |
| 순도 | >95% as determined by SDS-PAGE. |
| 관련 제품 | pH 7.4 Dilution Buffer |
| 정제 | Protein A/G purified from cell culture supernatant. |
| 등록번호 | Q3C2E2 |
| 형태 | Liquid |
| 저장 완충액 | 0.01M PBS pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 배경 | B-lymphocyte antigen CD20 (MS4A1) is a ~33 kDa protein. B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. CD20 is the therapeutic target of rituximab (MabThera) and obinutuzumab (Gazyva). |
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. |
SDS-PAGE for InVivoMAb Anti-Canine CD20 Antibody (Iv0177)
+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206
